AbSci Corp (ABSI) News

AbSci Corp (ABSI): $4.69

0.01 (+0.21%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add ABSI to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#312 of 357

in industry

Filter ABSI News Items

ABSI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ABSI News Highlights

  • For ABSI, its 30 day story count is now at 3.
  • Over the past 23 days, the trend for ABSI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DRUG, DEC and WASH are the most mentioned tickers in articles about ABSI.

Latest ABSI News From Around the Web

Below are the latest news stories about ABSCI CORP that investors may wish to consider to help them evaluate ABSI as an investment opportunity.

Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Absci management is scheduled to present on Thursday, January 11th at 10:30 a.m. Pacific Time (1:30 p.m. Eastern Time). Interested parties may access a live and archived webcast of the presentation on the company’s investor rela

Yahoo | December 28, 2023

Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline

Leading AI biologics and precision medicine innovators will harness technologies to build a diverse portfolio of novel drug treatments With this partnership, Absci achieves 2023 outlook of ten new Active Programs signed for the year VANCOUVER, Wash., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife®, a leading computational biology company driving precision medicine in complex chronic diseases, today announced a collaboration to dev

Yahoo | December 20, 2023

Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy

Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.

Yahoo | December 5, 2023

Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate

Collaboration Combines Absci’s AI Antibody Drug Creation Platform with AstraZeneca’s Expertise in Oncology Research and DevelopmentVANCOUVER, Wash., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a leader in generative AI antibody discovery, today announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target. This collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca'

Yahoo | December 4, 2023

AstraZeneca, AI biologics firm Absci tie up on cancer drug

Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics, the company said. It did not say what kind of cancer they plan to target. Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.

Yahoo | December 3, 2023

UPDATE 2-AstraZeneca, AI biologics firm Absci tie up on cancer drug

Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, Absci said in a statement on Sunday. Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics, the company said. Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.

Yahoo | December 3, 2023

Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY. Absci management is scheduled to present on Wednesday, November 29th at 10:50 a.m. Eastern Time (7:50 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: inv

Yahoo | November 15, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We're starting off Tuesday with a breakdown of all the biggest pre-market stock movers traders need to know about this morning!

William White on InvestorPlace | November 14, 2023

Absci Corp (ABSI) Reports Decrease in Q3 Revenue and Lower Net Loss Year-Over-Year

Partnership with Almirall and AI Drug Pipeline Unveiled Amid Financial Adjustments

Yahoo | November 14, 2023

Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results

Entered into partnership with Almirall to rapidly develop novel treatments for dermatological diseases, for up to $664M in deal value, plus royalties Unveiled AI drug creation pipeline of four wholly-owned assets VANCOUVER, Wash. and NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today reported financial and operating results for the quarter ended September 30, 2023. "Our recent achievements further demonstrate the value and p

Yahoo | November 14, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!